Table 5.
Novel positron emission tomography ligands commonly used in studying cognitive disorders
| Target | Ligands |
|---|---|
| Amyloid (novel ligands) | [11C]6-OH-BTA-1, Pittsburgh compound B |
| [11C]AZD2184 | |
| [11C]BF-227 | |
| [18F]Flutemetamol | |
| [18F]BAY94-9172, florbetaben | |
| [18F]AV-45, florbetapir | |
| Tubulin associated unit | [18F]THK523 |
| Neurotransmitters | |
| Dopamine | [18F]Flurodopa: dopa decarboxylation and vesicular storage |
| [18F/11C]FP-CIT and related: dopa transporter | |
| [11C]Raclopride: D2 receptor binding in basal ganglia | |
| [18F]Fallypride: D2 receptor binding in the cortex | |
| Serotonin | [11C]DASB and related: serotonin transporter |
| [11C]WAY-100635 and [18F]MPPF: 5-HT1A receptors | |
| [18F/11C]Altanserin, [11C]MDL-100907: 5-HT2A receptors | |
| Cholinergic | [11C]MP4A and related: acetyl choline esterase activity |
| [11C]Nicotine, [18F]A85380: nicotine receptors | |
| [11C]NMPB, [18F]FP-TZTP: muscarinergic receptors | |
| Neuroinflammation | [11C]Arachidonic acid: phospholipase enzymatic activity |
| [11C]Deprenyl: astrocytic activity irreversibly binds to the astrocytic enzyme monoamine oxidase B | |
| Microglia activation | [11C]PK-11195 |
| [11C]DAA1106 | |
| [11C]Vinpocetine | |